| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
FREMONT, Calif.—DiscoveRx Corp., which thus far has been known primarily for being the provider of the off-the-shelf HitHunter assays, has made things personal—or at least personalized—by launching custom labeling and profiling services.
 
The new services—custom labeling has been under­way since spring and pro­filing is set to begin in late July or August—are focused on kinases and proteases. DiscoveRx considers this effort to be a "major step" in its goal of giving wider access to its technology platform, enzyme fragment comple­mentation, which forms the core of the HitHunter prod­ucts used in drug discovery and screening.
 
"We have been known for providing out-of-the-box assay kits and tools," notes Sailaja Kuchibhatla, senior VP, business development for DiscoveRx. "Now drug dis­covery researchers and oth­ers can make custom assays of their choice and specify what they want. They can screen kinases they might not have been able to before and they can enjoy more specific formats for protease substrates."
 
Services include labeling of biomolecules with their beta-galactosidase enzyme donor (ED) tag for unactive and active kinase screening as well as synthesizing protease substrates with ED tags to enable chemiluminescent assays for new protease targets.
 
"The drug discovery commu­nity has been requesting broader access to our tools and technology, and by providing them access to customized services, we will enable them to screen against a wider variety of kinase or protease tar­gets," says Dr. Pyare Khanna, CEO of DiscoveRx.
 
Of particular interest to drug discovery researchers should be kinase binding assays, which Kuchibhatla says allow screening against active or unactive kinases. "We see a lot of traction in the mar­ketplace from these assays."
 
"With unactive kinases being increasingly important in drug discovery, it is critical to have a technology that allows one to rapidly develop quality assays," Khanna adds. "This service allows one to consider earlier targets that were intractable due to technology limitations."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A doctor wearing blue gloves and a white lab coat with a stethoscope around their neck holds a rendering of a digestive system on a glass pane with a swirled blue background.

Connecting the gut and liver to enhance drug development

Explore how a dual-organ microphysiological system connects human gut and liver tissue to bridge gaps in predicting how drugs behave in the body.
A syringe draws liquid from a glass vial, with several glass ampoules reflected on a glossy surface in the background

Turning up the heat: thermal analysis for biotherapeutics

Explore essential thermal stability techniques to ensure the safety, quality, and efficacy of biologic drugs.
A 3D-rendered image of a pink and white twisted RNA strand floating against a green, blurred cellular background.

Cutting the time and cost out of plasmid generation

Discover a hassle-free path to obtaining long, complex plasmid DNA.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue